*

Hitt og þetta 28. apríl 2006

Stem Cell Innovations, Inc. files patents relating to production of human motor neurons an

SCOTCH PLAINS, NJ - April 27, 2006 - Stem Cell Innovations, Inc. (OTCBB: SCLL) has filed a patent application protecting the differentiation of its proprietary human pluripotent stem cells (PCs) into neural progenitor cells and purified populations of motor neurons. These cells will initially be used in the Company's core drug discovery and toxicology platform. The Company is also exploring therapeutic applications of these cells.

Dr. James Kelly, CEO of Stem Cell Innovations, Inc. (SCI), stated, "These cells have significant potential in both drug discovery and cell therapies to treat diseases such as ALS, Parkinson's, Huntington's, Multiple Sclerosis, and Spinal Cord Injury. Obtaining and protecting neural progenitor cells, as well as purified populations of motor neurons from our PCs, is a significant step for the company." Kelly added, "We are already in discussions with companies that have expressed interest in these cells."

Stem Cell Innovations is actively seeking to make its PC cells widely available to universities and other not-for-profit institutions to rapidly advance the potential of the cells for the benefit of people and the Company.

Contact USA: Dr. James H. Kelly, Chief Executive Officer T +1 281 679-7900 Lawrence M. Gordon T +1 908 663-2150

Contact Europe Emmie van Halder, Business Development M +31 6 53 202 105, T +31 70 322 8050 Ellen de Waal, PR & Corporate Communications M +31 6 54 711 703, T +31 70 356 1534

About Stem Cell Innovations, Inc.

Stem Cell Innovations (SCI) is a cell biology company with offices in New Jersey, Houston, TX and Leiden, the Netherlands. SCI has developed and protected a unique pluripotent stem cell called the PC(TM). PCs have great potential in that they can be differentiated into virtually all cell types, and qualify for federal funding since PCs are not subject to the restrictions in National Institutes of Health funding imposed on ES cells. The PC program expands on the Company's currently marketed C3A human liver cell-based toxicology offerings.

For more information about SCI, visit the company's website at: www.stemcellinnovations.com